Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
Vincerx Pharma, Inc. Common Stock (VINC)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/30/2025: VINC (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
2 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $200
1 Year Target Price $200
| 1 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 211.24% | Avg. Invested days 32 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  5.0 |
| Profits based on simulation | Last Close 06/30/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 0.26M USD | Price to earnings Ratio - | 1Y Target Price 200 |
Price to earnings Ratio - | 1Y Target Price 200 | ||
Volume (30-day avg) 2 | Beta 1.48 | 52 Weeks Range 0.04 - 17.00 | Updated Date 06/30/2025 |
52 Weeks Range 0.04 - 17.00 | Updated Date 06/30/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -5.79 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -197.53% | Return on Equity (TTM) -3136.43% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value -4725287 | Price to Sales(TTM) - |
Enterprise Value -4725287 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -3.13 | Shares Outstanding 5234280 | Shares Floating 4665573 |
Shares Outstanding 5234280 | Shares Floating 4665573 | ||
Percent Insiders 4.12 | Percent Institutions 9.48 |
Analyst Ratings
Rating 2 | Target Price 200 | Buy 1 | Strong Buy 1 |
Buy 1 | Strong Buy 1 | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Vincerx Pharma, Inc. Common Stock
Company Overview
History and Background
Vincerx Pharma, Inc. is a biopharmaceutical company focusing on developing therapies for cancer. It was founded in 2019 and went public through a merger with a special purpose acquisition company (SPAC).
Core Business Areas
- Kinomodu2122 platform: This is Vincerx Pharma's small molecule drug discovery platform which is focused on discovering drugs which modulate kinase signaling.
- Bioconjugation/Antibody-Drug Conjugates (ADCs): The company is involved in the development of ADCs, which are designed to deliver cytotoxic payloads directly to cancer cells.
Leadership and Structure
Ahmed Hamdy, M.D., is the Chief Executive Officer. The company has a board of directors overseeing its strategic direction.
Top Products and Market Share
Key Offerings
- Competitors: Novartis, other big pharma companies focusing on oncology.
- Market Share Data or Users or Revenue: No Market Share due to products being in early stages
- VIP152: A small molecule CDK9 inhibitor under development for hematological malignancies. Currently in clinical trials. Competitors include other companies developing CDK9 inhibitors, such as those from Novartis and other big pharma companies focusing on oncology.
- Competitors: Other ADC developers in hematological malignancies
- Market Share Data or Users or Revenue: No Market Share due to products being in early stages
- VIP943: An antibody-drug conjugate (ADC) targeting CD123. CD123 is overexpressed in several hematologic malignancies. Currently in clinical trials. Competitors include other companies developing ADCs for hematological malignancies.
Market Dynamics
Industry Overview
The biopharmaceutical industry is highly competitive, with significant investments in research and development. The oncology sector is a key area of focus, driven by high unmet medical needs.
Positioning
Vincerx Pharma is a clinical-stage company aiming to develop differentiated cancer therapies through its Kinomodu2122 platform and ADC technologies. Its competitive advantage depends on the success of its clinical trials and the differentiation of its products.
Total Addressable Market (TAM)
The oncology market is estimated to be in the hundreds of billions of dollars. Vincerx Pharma is targeting specific segments within this market, and its TAM depends on the target indications and the success of its pipeline.
Upturn SWOT Analysis
Strengths
- Proprietary Kinomodu2122 drug discovery platform
- ADC development capabilities
- Experienced leadership team
- Focus on oncology, a high-growth area
Weaknesses
- Clinical-stage company with no approved products
- High cash burn rate
- Dependence on successful clinical trial outcomes
- Relatively small market capitalization
Opportunities
- Positive clinical trial results could lead to significant value creation
- Potential partnerships with larger pharmaceutical companies
- Expansion of pipeline through internal discovery or acquisitions
- Advancements in ADC technology
Threats
- Clinical trial failures
- Competition from larger pharmaceutical companies
- Regulatory hurdles
- Changes in the market landscape
- Inability to raise additional capital
Competitors and Market Share
Key Competitors
- NVS
- MRK
- PFE
- BMY
- AZN
Competitive Landscape
Vincerx Pharma is a smaller player in a competitive landscape dominated by larger pharmaceutical companies. Its success depends on innovation and differentiation.
Growth Trajectory and Initiatives
Historical Growth: No historical revenue growth, as the company is in the clinical stage.
Future Projections: Future growth depends on the success of VIP152 and VIP943 clinical trials. Analyst estimates vary widely based on clinical trial outcomes.
Recent Initiatives: Advancing VIP152 and VIP943 through clinical trials, exploring potential partnerships, and continuing research on Kinomodu2122 platform.
Summary
Vincerx Pharma is a clinical-stage biopharmaceutical company focused on oncology. Its strengths lie in its Kinomodu2122 platform and ADC development capabilities. However, it faces challenges due to its high cash burn and dependence on successful clinical trial outcomes. Positive clinical trial results are crucial for future growth.
Peer Comparison
Sources and Disclaimers
Data Sources:
- SEC Filings (10-K, 10-Q)
- Company Website
- Press Releases
- Analyst Reports
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. The data is based on publicly available information and may be subject to change. Past performance is not indicative of future results.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Vincerx Pharma, Inc. Common Stock
Exchange NASDAQ | Headquaters San Mateo, CA, United States | ||
IPO Launch date 2020-05-27 | Co-Founder, Acting CEO, Secretary & Director Dr. Raquel E. Izumi Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 12 | Website https://vincerx.com |
Full time employees 12 | Website https://vincerx.com | ||
Vincerx Pharma, Inc. operates as a clinical-stage biopharmaceutical company that develops differentiated and novel therapies to address the unmet medical needs of patients with cancer in the United States. Its VersAptx bioconjugation platform combines different targeting, linker, and payload technologies to develop antibody-drug conjugates (ADC) and small molecule drug conjugates (SMDC); and provides CellTrapper technology for use in reduction of payload cellular permeability. The company develops VIP943, an antibody drug conjugate in Phase 1 dose-escalation study for relapsed/refractory acute myeloid leukemia, higher-risk MDS, and B-cell acute lymphoblastic leukemia; VIP236, an SMDC, which is in Phase 1 dose-escalation study for the treatment of patients with advanced or metastatic solid tumors; and VIP924, an anti-CXCR5 ADC that leverages the same effector chemistry in preclinical studies for b-cell malignancies. It has a collaboration with the National Institutes of Health for the Phase 1 dose-escalation of enitociclib, a highly selective cyclin-dependent kinase 9 inhibitor. The company was formerly known as Vincera Pharma, Inc. and changed its name to Vincerx Pharma, Inc. in January 2021. Vincerx Pharma, Inc. was founded in 2019 and is headquartered in San Mateo, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.